Des-γ-Carboxy Prothrombin and α-Fetoprotein as Biomarkers for the Early Detection of Hepatocellular Carcinoma

Gastroenterology

Volumn 138, Issue 2, 2010, Pages 493-502

  Lok, Anna S ^a   Sterling, Richard K ^b   Everhart, James E ^c   Wright, Elizabeth C ^c   Hoefs, John C ^d   Di Bisceglie, Adrian M ^e   Morgan, Timothy R ^d,f   Kim, Hae Young ^g   Lee, William M ^h   Bonkovsky, Herbert L ⁱ   Dienstag, Jules L ^j  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^g NEW ENGLAND RESEARCH INSTITUTES   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; DECARBOXYPROTHROMBIN;

ADULT; AGED; ARTICLE; CANCER SCREENING; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; FEMALE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

EID: 75449103932     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.10.031     Document Type: Article

References (39)

1. Kamangar F., Dores G.M., and Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24 (2006) 2137-2150
2. El-Serag H.B. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127 (2004) S27-S34
3. Everhart J.E. Primary liver cancer. In: Everhart J.E. (Ed). Burden of digestive diseases in the United States. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (2008), US Government Printing Office, Washington, DC 49-52 NIH Publication No. 09-6443 2008
4. Stravitz R.T., Heuman D.M., Chand N., et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med 121 (2008) 119-126
5. Bruix J., and Sherman M. Management of hepatocellular carcinoma. Hepatology 42 (2005) 1208-1236
6. Zhang B.H., Yang B.H., and Tang Z.Y. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130 (2004) 417-422
7. McMahon B.J., Bulkow L., Harpster A., et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 32 (2000) 842-846
8. Bruix J., Sherman M., Llovet J.M., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35 (2001) 421-430
9. Makuuchi M., Kokudo N., Arii S., et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 38 (2008) 37-51
10. Aoyagi Y., Oguro M., Yanagi M., et al. Clinical significance of simultaneous determinations of α-fetoprotein and des-γ-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma. Cancer 77 (1996) 1781-1786
11. Nomura F., Ishijima M., Kuwa K., et al. Serum des-γ-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma. Am J Gastroenterol 94 (1999) 650-654
12. Mita Y., Aoyagi Y., Yanagi M., et al. The usefulness of determining des-γ-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer 82 (1998) 1643-1648
13. Ishii M., Gama H., Chida N., et al. Simultaneous measurements of serum α-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol 95 (2000) 1036-1040
14. Hamamura K., Shiratori Y., Shiina S., et al. Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-γ-carboxy prothrombin and low serum α-fetoprotein. Cancer 88 (2000) 1557-1564
15. Nakamura S., Nouso K., Sakaguchi K., et al. Sensitivity and specificity of des-γ-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 101 (2006) 2038-2043
16. Okuda H., Obata H., Nakanishi T., et al. Production of abnormal prothrombin (des-γ-carboxy prothrombin) by hepatocellular carcinoma. A clinical and experimental study. J Hepatol 4 (1987) 357-363
17. Liebman H.A., Furie B.C., Tong M.J., et al. Des-γ-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 310 (1984) 1427-1431
18. Stenflo J., Fernlund P., Egan W., et al. Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci U S A 71 (1974) 2730-2733
19. Marrero J.A. Screening tests for hepatocellular carcinoma. Clin Liver Dis 9 (2005) 235-251
20. Ikoma J., Kaito M., Ishihara T., et al. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-γ-carboxy prothrombin: a prospective study. Hepatogastroenterology 49 (2002) 235-238
21. Pateron D., Ganne N., Trinchet J.C., et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 20 (1994) 65-71
22. Oka H., Tamori A., Kuroki T., et al. Prospective study of α-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 19 (1994) 61-66
23. Bolondi L., Sofia S., Siringo S., et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost-effectiveness analysis. Gut 48 (2001) 251-259
24. Tong M.J., Blatt L.M., and Kao V.W. Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. J Gastroenterol Hepatol 16 (2001) 553-559
25. Chalasani N., Horlander Sr. J.C., Said A., et al. Screening for hepatocellular carcinoma in patients with advanced cirrhosis. Am J Gastroenterol 94 (1999) 2988-2993
26. Izuno K., Fujiyama S., Yamasaki K., et al. Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-γ-carboxy prothrombin and α-fetoprotein: a prospective study. Hepatogastroenterology 42 (1995) 387-393
27. Lee W.M., Dienstag J.L., Lindsay K.L., et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 25 (2004) 472-492
28. Di Bisceglie A.M., Shiffman M.L., Everson G.T., et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 359 (2008) 2429-2441
29. Di Bisceglie A.M., Sterling R.K., Chung R.T., et al. Serum α-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 43 (2005) 434-441
30. Ishak K., Baptista A., Bianchi L., et al. Histological grading and staging of chronic hepatitis. J Hepatol 22 (1995) 696-699
31. Lok A.S., Seeff L.B., Morgan T.R., et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 136 (2009) 138-148
32. Gupta S., Bent S., and Kohlwes J. Test characteristics of α-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med 139 (2003) 46-50
33. Marrero J.A., Su G.L., Wei W., et al. Des-γ carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 37 (2003) 1114-1121
34. Lamerz R., Runge M., Stieber P., et al. Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases. Anticancer Res 19 (1999) 2489-2493
35. Toyoda H., Kumada T., Osaki Y., et al. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin Gastroenterol Hepatol 4 (2006) 1528-1536
36. Volk M.L., Hernandez J.C., Su G.L., et al. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark 3 (2007) 79-87
37. Yano Y., Yamashita F., Kuwaki K., et al. Clinical features of hepatitis C virus-related hepatocellular carcinoma and their association with α-fetoprotein and protein induced by vitamin K absence or antagonist-II. Liver Int 26 (2006) 789-795
38. Nguyen M.H., Garcia R.T., Simpson P.W., et al. Racial differences in effectiveness of α-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology 36 (2002) 410-417
39. Beale G., Chattopadhyay D., Gray J., et al. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer 8 (2008) 200